Depression, Major Depressive Disorder
Conditions
Brief summary
The Investigators are conducting a research study to learn about the safety and benefit of using a medication called buprenorphine for patient with difficult to treat depression . This research study is testing whether combining two medications will be effective in treating depression when initial treatment with just one antidepressant does not relieve the depressive symptoms ; this is what is called difficult to treat depression or treatment resistant depression . The two medication the investigators are using are an anti-depressant medication called venlafaxine XR ( the generic form of Effexor ) and buprenorphine . Buprenorphine is a medication that is FDA approved for the treatment of opioid dependence. The investigators are testing whether adding buprenorphine to venlafaxine enhances treatment response.
Detailed description
The aim of this study is to examine the feasibility, safety, and tolerability of buprenorphine (BPN) as a novel treatment for late-life treatment resistant depression (LL-TRD). The investigators aim to use a clinical trial methodology common to all three sites, and to examine the mechanism of action (MOA) of BPN using translational neuroscience methods. Over ½ of seniors with depression fail to respond to traditional antidepressants.19,20 Modulation of the opiate system with BPN offers a novel mechanistic approach to improve the lives of patients with LL-TRD, with a safety profile potentially superior to current augmentation strategies such as antipsychotics, lithium, ECT, and surgical interventions (e.g., deep brain or vagal nerve stimulation).
Interventions
DRUGvenlafaxine
slow titration to a maximum of 300 mg per day. will remain on venlafaxine XR for upto 32 weeks.
DRUGbuprenorphine
randomized to either buprenorphine or placebo, dose range from 0.2 mg qd/ to 1.2 mg qd
DRUGplacebo
patients will remain on venlafaxine XR and be randomzied to receive either placebo or buprenorphine for 8 weeks. at the end of 8 weeks those who did not receive buprenorphine will be given an opportunity to try it.
Sponsors
Reckitt Benckiser LLC
Centre for Addiction and Mental Health
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age \> 50 years 2. Major depressive disorder (MDD), single or recurrent, as diagnosed by the SCID-IV (or SCID-5 if available) 3. MADRS \> 15 4. Has or agrees to establish a clinical relationship with primary care physician (PCP). 5. Availability of an informant (e.g., emergency contact) is encouraged but not required for study participation
Exclusion criteria
1. Inability to provide informed consent 2. Depressive symptoms not severe enough (i.e., MADRS \< 15) at the baseline assessments 3. Dementia, as defined by 3MS \< 80 and clinical evidence of dementia 4. Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms, as diagnosed by the SCID 5. Abuse of or dependence on alcohol or other substances within the past 3 months as determined by SCID, and score of \> 8 on AUDIT-C and confirmed by study physician interview 6. High risk for suicide (e.g., active SI and/or current/recent intent or plan) AND unable to be managed safely in the clinical trial (e.g., unwilling to be hospitalized). Urgent psychiatric referral will be made in these cases 7. Contraindication to venlafaxine or buprenorphine as determined by PCP and study physician including history of intolerance of either venlafaxine or buprenorphine in the study target dosage range (venlafaxine at up to 300 mg/day; buprenorphine at up to 1.2 mg/day) 8. Inability to communicate in English (i.e., interview cannot be conducted without an interpreter; subject largely unable to understand questions and cannot respond in English) 9. Non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview) 10. Unstable medical illness, including delirium, uncontrolled diabetes mellitus, hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that are not under medical management. This will be determined based on information from the patient's personal physician and study physician's clinical judgment. Referral to the patient's personal physician or to a general practitioner will be made in these cases 11. Subjects taking psychotropic medications that cannot be safely tapered and discontinued prior to study initiation. The following exceptions are allowed if they have been taken at a stable dose for at least 4 weeks prior to study entry and there is not a plan to change the dose during the next 32 -36 weeks: benzodiazepines up to 2 mg/d lorazepam equivalent; other sedative-hypnotics (e.g., zolpidem, zaleplon, eszopiclone); gabapentin if prescribed for non-psychiatric indication (e.g., neuropathy) 12. History of opiate abuse or dependence 13. Severe pain, defined as \> 7 on 0-10 numeric rating scale for pain 14. Concomitant use of strong or moderate CYP3A4 inhibitor (indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketonazole, nefazodone, saquinovir, telithromycin, aprepitant, erythromycin, fluconazole, grapefruit juice, verapamil, diltiazem) 15. Refusal to stop all opioids (to avoid precipitating opioid withdrawal) 16. Refusal to discontinue all alcohol (to reduce the risk of respiratory depression) 17. Hepatic impairment (AST/ALT \> 1.5 times upper normal) 18. Estimated Glomerular Filtration Rate (GFR) \< 20 ml/min 19. Inability/refusal to identify a person as an emergency contact \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Montgomery-Asberg Depression Rating Scale | 32 weeks | MADRS at baseline will establish study eligibility and will assess treatment-sensitive change in MDD. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Suicidal Ideation Scale ( SIS) | 32 weeks | Assess suicidal ideation and previous suicide attempts |
| Brief Symptom Inventory for Anxiety | 32 weeks | — |
| Numeric Scale of Pain ( NRS-P) | 16 weeks | — |
| Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) | 16 weeks | Assess overall burden or degree of interference in day-to-day activities and function due to the side effects attributable specifically to the antidepressant (in this case, buprenorphine) treatment |
| Antidepressant Side Effect Checklist (ASEC) | 16 weeks | Assessment of side- effects |
Countries
Canada
Outcome results
None listed